Food and Drug Administration
Pulmonary-Allergy Drugs Advisory Committee
September 6, 2002
Briefing Information
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Spiriva® (tiotropium bromide) Inhalation Powder, NDA 21-395, Boehringer Ingelheim Pharmaceuticals, Inc. pdf
Memo dated August 6, 2002, from Division Director to Committee Members doc htm pdf
Disclaimer Statement doc htm pdf
Clinical Briefing Document Spiriva® (tiotropium bromide) Inhalation Powder for COPD doc htm pdf
Clinical Briefing Part 1 pdf
Clinical Briefing Part 1-A pdf
Clinical Briefing Part 2 pdf
Clinical Pharmacology and Biopharmaceutics Briefing Document doc htm pdf